Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)

Subgroup experienced efficacy and safety consistent with overall study population Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers LOS ANGELES, March 17, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers w ...